Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.
Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.